List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 25 studies with search of:   "SuperGen" [Exact]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
2 Recruiting MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: multitargeted receptor tyrosine kinase inhibitor MP470;   Procedure: laboratory biomarker analysis;   Procedure: pharmacological study;   Procedure: positron emission tomography
3 Recruiting Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Condition: Tumors
Intervention: Drug: Rubitecan
4 Completed Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
5 Recruiting Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Rubitecan
6 Active, not recruiting Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: rubitecan
7 Active, not recruiting Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: mitomycin C;   Drug: rubitecan
8 Active, not recruiting Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil;   Drug: rubitecan
9 Completed Nitrocamptothecin in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: rubitecan
10 Completed Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: rubitecan
11 Terminated Dose-Finding Study Using Pentostatin for Injection in the Treatment of Steroid-Refractory aGvHD
Condition: Acute Graft Versus Host Disease
Intervention: Drug: pentostatin for injection
12 Completed Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
Conditions: Gastrointestinal Stromal Tumor;   Sarcoma;   Small Intestine Cancer
Intervention: Drug: rubitecan
13 Completed Nitrocamptothecin in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: rubitecan
14 Recruiting MP470 and Chemotherapy in Treating Patients With Cancer
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin;   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Drug: etoposide;   Drug: multitargeted receptor tyrosine kinase inhibitor MP470;   Drug: paclitaxel;   Drug: topotecan hydrochloride
15 Active, not recruiting Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
Conditions: Esophageal Cancer;   Gastric Cancer
Intervention: Drug: rubitecan
16 Active, not recruiting Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: rubitecan
17 Completed Decitabine Versus Supportive Care in Adults With Advanced-Stage MDS
Condition: Myelodysplastic Syndrome
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
18 Completed Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: decitabine (5-aza-2'deoxycytidine)
19 Recruiting Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Nipent, Cytoxan, Rituxan
20 Active, not recruiting Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Pentostatin;   Drug: Tacrolimus;   Drug: Methotrexate

Previous Page Studies Shown (1-20) Next (21-25)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services